...
首页> 外文期刊>Cytometry, Part A: the journal of the International Society for Analytical Cytology >An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data
【24h】

An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data

机译:一个R型流动过程,分析正常和恶性人骨髓典型流式细胞术数据的无监督聚类

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Multiparameter flow cytometry (MFC) is a powerful and versatile tool to accurately analyze cell subsets, notably to explore normal and pathological hematopoiesis. Yet, mostly supervised subjective strategies are used to identify cell subsets in this complex tissue. In the past few years, the implementation of mass cytometry and the big data generated have led to a blossoming of new software solutions. Their application to classical MFC in hematology is however still seldom reported. Here, we show how one of these new tools, the FlowSOM R solution, can be applied, together with the Kaluza (R) software, to a new delineation of hematopoietic subsets in normal human bone marrow (BM). We thus combined the unsupervised discrimination of cell subsets provided by FlowSOM and their expert-driven node-by-node assignment to known or new hematopoietic subsets. We also show how this new tool could modify the MFC exploration of hematological malignancies both at diagnosis (Dg) and follow-up (FU). This can be achieved by direct comparison of merged listmodes of reference normal BM, Dg, and FU samples of a representative acute myeloblastic case tested with the same immunophenotyping panel. This provides an immediate unsupervised evaluation of minimal residual disease. (c) 2019 International Society for Advancement of Cytometry
机译:MultiParameter流式细胞术(MFC)是一种强大而通用的工具,可准确地分析细胞亚群,特别是探索正常和病理造血。然而,主要监督主观策略用于识别该复杂组织中的细胞亚群。在过去的几年中,大规模细胞测定法的实施和产生的大数据导致了新的软件解决方案的开花。然而,他们在血液学中养殖MFC的应用仍然很少报道。在这里,我们展示了这些新工具,流动r解决方案中的一个如何与Kaluza(R)软件一起应用于正常人骨髓(BM)中的造血子集的新描绘。因此,我们组合了流量和其专家驱动的节点逐个分配给已知或新的造血子集的细胞子集的无监督辨别。我们还展示了这款新工具如何修改诊断(DG)和随访(FU)的血液恶性肿瘤的MFC探索。这可以通过用相同免疫表型面板测试的代表性急性髓细胞混合物壳的参考法正常BM,DG和FU样品的合并列表来实现。这提供了对最小残留疾病的立即无监督评估。 (c)2019年国际促进细胞计量协会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号